India's Shilpa joins HIV patent pool
This article was originally published in Scrip
Executive Summary
The Indian active pharmaceutical ingredient (API) and dosage form firm, Shilpa Medicare, is to produce five key HIV medicines for sale in 100–112 countries, expanding access to treatments for HIV/AIDS under an agreement signed with the Medicines Patent Pool (MPP) and Gilead Sciences.